of downloading the files as he left to take a similar role at Pfizer (PFE). Files containing 10-year business plans across ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Sangamo said that Pfizer had informed the company of its intention to file regulatory applications for giroctocogene fitelparvovec in the United States and EU in early 2025. Sangamo was eligible ...